hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06361693, orgStudyIdInfo id: APHP240147, secondaryIdInfos id: 2024-A00143-44, type: OTHER, domain: France : Ministry of Health, briefTitle: Descriptive Observational Study of Patient-performed Pre-oxygenation, acronym: ApréOx, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: The aim of this research would be to determine the efficacy and effects of preoxygenation when performed by the patient (mask held by the patient).This is the concept of "self-preoxygenation"., conditionsModule conditions: Anesthesia, conditions: Anxiety, conditions: ASA Physical Status I, conditions: ASA Physical Status II, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: Auto-preoxygenation, interventions name: APAIS scale, interventions name: Visual analog anxiety scale (VAS-A), interventions name: Visual analog comfort scale (VAS-C), outcomesModule primaryOutcomes measure: FeO2>90%, secondaryOutcomes measure: APAIS anxiety score, secondaryOutcomes measure: Visual analog anxiety scale (VAS-A) score, secondaryOutcomes measure: Visual analog anxiety scale (VAS-A) score, secondaryOutcomes measure: Visual analog comfort scale (VAS-C) score, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Anesthesia-intensive care department - Cochin - Port-Royal hospital - APHP, city: Paris, state: Ile De France, zip: 75014, country: France, contacts name: Sophie TOUSSAINT, Nurse anesthetist, role: CONTACT, phone: 00 33 1 58 41 45 17, email: sophie.toussaint@aphp.fr, contacts name: Claude LE STANG, Nurse anesthetist, role: CONTACT, email: cch.grouperecherche@gmail.com, contacts name: Christophe BAILLARD, PUPH, role: SUB_INVESTIGATOR, geoPoint lat: 48.85341, lon: 2.3488, hasResults: False
protocolSection identificationModule nctId: NCT06361680, orgStudyIdInfo id: Coenzyme Q10 on diabetic child, briefTitle: Effect of Coenzyme Q10 on Diabetic Children, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-10-30, primaryCompletionDateStruct date: 2025-10-30, completionDateStruct date: 2025-11-30, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Determine the effect of Coenzyme Q10 on random blood sugar and glycosylated haemoglobin, conditionsModule conditions: Type 1 Diabetes Mellitus, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SCREENING, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets, outcomesModule primaryOutcomes measure: Assess the effect of Coenzyme Q10 on glycated haemoglobin in type 1 diabetes mellitus, secondaryOutcomes measure: Control of random blood sugar and glycated haemoglobin in children with type 1 diabetes mellitus ., eligibilityModule sex: ALL, minimumAge: 2 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06361667, orgStudyIdInfo id: 1/02.02.2024, briefTitle: Culture and Well-being: Art as Prescription Therapy ("Art on Prescription"), acronym: AoP, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2025-01-15, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: KAVADIA ELENI, class: OTHER, descriptionModule briefSummary: Cluster randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL)., conditionsModule conditions: Mental Health Issue, conditions: Anxiety Disorders, conditions: Depressive Disorder, conditions: Emotional Disorder, conditions: Schizophrenia, conditions: Autism, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: We will follow standard practice for RCTs and apply an ANCOVA model to estimate the effects of treatment. The formalism is:y \~ b0 + b1xtreatment_group + b2xtime + b3xtreatment_groupxtime + covariates (1)Where, y is each outcome, b1-b3 are the regression coefficients and covariates denotes covariates at randomisation (DETERMINE)The inference of interest for the model concerns b3, the interaction term, as we posit that there will be a difference in slopes between the treatment groups.The inference is going to happen via an estimation of the t-statistic, defined as follows"t = b3/SE (2)Where SE is the standard error for coefficient b3t \> 1.96 (3)And 1.96 is the critical value for statistical significance at alpha = 0.05., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 384, type: ESTIMATED, armsInterventionsModule interventions name: Arts, outcomesModule primaryOutcomes measure: The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), secondaryOutcomes measure: Generalised Anxiety Disorder Assessment (GAD-7), secondaryOutcomes measure: The Patient Health Questionnaire-9 (PHQ-9), secondaryOutcomes measure: UCLA 3-item Loneliness Scale, secondaryOutcomes measure: The Strengths and Difficulties Questionnaire (SDQ), eligibilityModule sex: ALL, minimumAge: 10 Years, maximumAge: 99 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Eleni Kavadia, status: RECRUITING, city: Athens, country: Greece, contacts name: Eleni Kavadia, role: CONTACT, phone: +30 210 6170804, email: ekavadia@epipsi.gr, contacts name: Nikos Stefanis, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.97945, lon: 23.71622, documentSection largeDocumentModule largeDocs typeAbbrev: Prot, hasProtocol: True, hasSap: False, hasIcf: False, label: Study Protocol, date: 2024-03-10, uploadDate: 2024-03-26T12:19, filename: Prot_000.pdf, size: 390364, hasResults: False
protocolSection identificationModule nctId: NCT06361654, orgStudyIdInfo id: 2023/0135/OB, briefTitle: Effect of Muscular Imbalance Between Flexors and Extensors of the Fingers and Wrist on Upper Limb Injuries in Climbers, acronym: CRIMPER, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2025-03-25, completionDateStruct date: 2025-09-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-15, sponsorCollaboratorsModule leadSponsor name: University Hospital, Rouen, class: OTHER, descriptionModule briefSummary: Climbing is a booming sport with an increasing number of participants. When practicing this sport, there is a muscular imbalance between the flexor and extensor systems (especially in the fingers), with the flexors of the fingers exerting greater force than the extensors. In addition, upper limb injuries, particularly the fingers, are very common.The study will be carried out on club-licensed climbers, as they are better supervised. They will be recruited through requests sent to various clubs. The measurements will be taken during different climbing sessions, after the warm-up.The study will include measurements on different climbers. Informed consent and personal data will be collected from the climbers before the measurements are taken. The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer. The climbers will then continue their usual training for 1 year. For 1 year after the measurements, the climbers will be contacted every month by telephone to collect the different injuries they may have suffered in relation to climbing, as well as the number of hours they have spent climbing in the past month. After 1 year, the annual number of hours of climbing and the annual number of injuries can be calculated for each climber. Injury is defined as any medically diagnosed lesion of the musculoskeletal system of the upper limb or pain that prevents the practice of a sport whose aetiology is climbing. These data are used to calculate the "athlete exposure" (A-E), i.e. the incidence of injury per 1000 hours of practice. As the study population is large, this allows for variations in exposure between subjects., conditionsModule conditions: Climber, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 47, type: ESTIMATED, armsInterventionsModule interventions name: The strength values of the flexors and extensors of the fingers and wrist will be measured using a dynamometer, outcomesModule primaryOutcomes measure: Athlete exposure, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rouen, University Hospital, status: RECRUITING, city: Rouen, state: Normandie, zip: 76031, country: France, contacts name: timothee gillot, phd, role: CONTACT, phone: 0232880671, phoneExt: +33, email: timothee.gillot@chu-rouen.fr, geoPoint lat: 49.44313, lon: 1.09932, hasResults: False
protocolSection identificationModule nctId: NCT06361641, orgStudyIdInfo id: 49RC23_0259, secondaryIdInfos id: AO2721-44, type: OTHER, domain: ANSM, briefTitle: Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes, acronym: PHEMOP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2025-10-19, completionDateStruct date: 2027-10-19, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University Hospital, Angers, class: OTHER_GOV, descriptionModule briefSummary: Prospective study for functional and phenotypic characterization of monocytes in philadelphia-negative myeloproliferative neoplasms, conditionsModule conditions: Myeloproliferative Neoplasm, conditions: Polycythemia Vera, conditions: Essential Thrombocythemia, conditions: Primary Myelofibrosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Monocytes signatures in myeloproliferative neoplasms at diagnosis, outcomesModule primaryOutcomes measure: WHO 2016 criteria for polycythemia vera, prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis, secondaryOutcomes measure: Identify correlation between the monocytic signature and driver mutations (mutation in JAK2, CALR or MPL gene)., secondaryOutcomes measure: Identify correlation between the monocytic signature and the grade of fibrosis, secondaryOutcomes measure: prognostic value of the monocytic signature using a principal component analysis Response criteria according to Barosi et al., Leukemia, vol. 29,1 (2015): 20-6, secondaryOutcomes measure: Prognostic value of the monocyte signature for disease worsening according to Sureau et al., Blood Cancer Journal, vol. 12,4, 56. 8 Apr. 2022, secondaryOutcomes measure: leukemia-free survival, secondaryOutcomes measure: myelofibrosis-free survival, secondaryOutcomes measure: Monocytes parameters for hematological progression, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: GOUBAND Agathe, city: Angers, state: Maine Et Loire, zip: 49933, country: France, contacts name: Agathe GOUBAND, PharmD, role: CONTACT, phone: 02 41 35 55 96, phoneExt: 33, email: Agathe.Gouband@chu-angers.fr, contacts name: Damien LUQUE PAZ, PharmD, role: CONTACT, phone: 02 41 35 53 53, phoneExt: 33, email: Damien.LuquePaz@chu-angers.fr, geoPoint lat: 47.46667, lon: -0.55, locations facility: BESCOND Charles, city: Cholet, state: Maine Et Loire, zip: 49325, country: France, contacts name: Charles BESCOND, MD, role: CONTACT, phone: 0241355880, email: charles.bescond@ch-cholet.fr, geoPoint lat: 47.06667, lon: -0.88333, locations facility: TRUCHAN-GRACZYK Malgorzata, city: Saumur, state: Maine Et Loire, zip: 49400, country: France, geoPoint lat: 47.26667, lon: -0.08333, hasResults: False
protocolSection identificationModule nctId: NCT06361615, orgStudyIdInfo id: CEC_FP_2023042, briefTitle: Effect of a Dual-task Intervention Program on Physical and Cognitive Function, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-11-08, primaryCompletionDateStruct date: 2024-03-05, completionDateStruct date: 2024-04-05, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: University of Americas, class: OTHER, descriptionModule briefSummary: Aim: to compare the effects of single-task (ST) and dual-task (DT) training on physical and cognitive function in institutionalized older adults in 1 month.Methods: Participants were assigned randomly into two groups, ST (multicomponent physical exercise) and DT training (multicomponent physical exercise + cognitive tasks). Both groups performed the exercise three times per week for 1 month. Short Physical Performance Battery (SPPB), handgrip strength, Barthel Index and Montreal Cognitive Assessment (MoCA) were used to assess physical and cognitive performance, respectively. Variables were measured at the beginning (V1),at the end of the exercise (V2), as well as one month later (V3). Paired Student's t-test and lineal logistic regressions models were used to explore the effect of the exercise interventions., conditionsModule conditions: Functional Movement Disorder, conditions: Fragility, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Parallel Assignment, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: Although blinding is not possible for participants in exercise-intervention research, the outcome assessors and data analysts were masked to group assignments. The study was unblinded after the statistical analyses were completed., whoMasked: PARTICIPANT, enrollmentInfo count: 24, type: ACTUAL, armsInterventionsModule interventions name: Single-Task, interventions name: Dual-Task, outcomesModule primaryOutcomes measure: Short Physical Performance Battery (SPPB), secondaryOutcomes measure: Montreal Cognitive Assessment (MoCA), secondaryOutcomes measure: Barthel Index, secondaryOutcomes measure: Isometric Handgrip Strength (IHS), secondaryOutcomes measure: Immobility Syndrome Scale, eligibilityModule sex: ALL, minimumAge: 65 Years, maximumAge: 75 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Universidad de las Americas, city: Santiago de Chile, state: Santiago, zip: 7750495, country: Chile, geoPoint lat: -33.45694, lon: -70.64827, hasResults: False
protocolSection identificationModule nctId: NCT06361602, orgStudyIdInfo id: SYSKY-2023-1015-01, briefTitle: Exploring the Effectiveness and Factors Affecting the Collection of Single Nucleated Cells From Different Volunteers, acronym: SYX-AN-01, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2027-05-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, class: OTHER, descriptionModule briefSummary: 1. 80 cases of healthy donors were subjected to peripheral blood single nucleated cells (PBMC) collection and analyzed the effects of age, body mass index (BMI), blood routine indexes before collection, collection of circulating blood volume, volume of processed blood and the number of circulations, etc., on the PBMC obtained from both men and women, and explored the effects of PBMC collection in different volunteers and the factors affecting the collection. and the influencing factors.2. The data obtained will provide a reference for the MNC threshold for the subsequent clinical trials of immunocell therapy in hospitals.3. From the screening of volunteers, PBMC collection and transportation conditions and other specific details of the operation, risk assessment and the establishment of a safe operation standard process, for the hospital to carry out subsequent clinical trials of immune cell therapy to provide an effective reference., conditionsModule conditions: Observational Study, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: inapplicable, outcomesModule primaryOutcomes measure: Exploring the effectiveness and factors affecting the collection of single nucleated cells from different volunteers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06361589, orgStudyIdInfo id: EK2023003-1, briefTitle: Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-11-01, completionDateStruct date: 2028-11-01, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Sichuan Cancer Hospital and Research Institute, class: OTHER, descriptionModule briefSummary: This study was a multicenter, prospective, non-interventional clinical study that included first-line and late-line patients with advanced non-small cell lung cancer with ALK fusions treated with the third generation ALK-TKI lorlatinib until disease progression, intolerable toxicity, investigator or subject decision to withdraw, lost to follow-up, initiation of other antineoplastic therapy, or death. Clinical pathology including sex, age, ALK mutation status at diagnosis, and clinical stage at diagnosis were collected from medical records. Physical condition as assessed by ECOG-PS before administration of lorlatinib was also recorded. Treatment information was obtained from the records, including dose and timing of ALK-TKI therapy and tumor response, number of prior systemic lines of therapy, and local treatment modalities such as radiotherapy and surgery. Quality of life based on the EORTC QLQ C30+LC29 scale (plus the EORTC QLQ BN20 scale in patients with brain/meningeal metastases) was performed at baseline and at each follow-up point. This study will use REDCap platform to collect and manage the study data information of multi-center patients., conditionsModule conditions: ALK-positive Non-small Cell Lung Cancer, conditions: Real World Study, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Lorlatinib, outcomesModule primaryOutcomes measure: PFS, secondaryOutcomes measure: OS, secondaryOutcomes measure: ORR, secondaryOutcomes measure: AE, secondaryOutcomes measure: PRO1, secondaryOutcomes measure: PRO2, secondaryOutcomes measure: PRO3, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sichuan cancer hospital, status: RECRUITING, city: Chengdu, state: Sichuan, zip: 610000, country: China, contacts name: Juan Li, MD, role: CONTACT, phone: 13880276636, email: dr.lijuan@hotmail.com, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06361576, orgStudyIdInfo id: CA209-1443, briefTitle: Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-05, primaryCompletionDateStruct date: 2024-01-25, completionDateStruct date: 2024-01-25, studyFirstPostDateStruct date: 2024-04-12, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Bristol-Myers Squibb, class: INDUSTRY, descriptionModule briefSummary: The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab., conditionsModule conditions: Upper Gastrointestinal Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 700, type: ACTUAL, armsInterventionsModule interventions name: Nivolumab, outcomesModule primaryOutcomes measure: Particpant sociodemographics, primaryOutcomes measure: Participant Eastern Cooperative Oncology Group (ECOG) score, primaryOutcomes measure: Participant HER2 status, primaryOutcomes measure: Participant comorbidities, primaryOutcomes measure: Participant tumour location, primaryOutcomes measure: Participant treatment history, secondaryOutcomes measure: Initial nivolumab dosage prescribed to participants, secondaryOutcomes measure: Number of nivolumab treatments received by participants, secondaryOutcomes measure: Planned combination chemotherapy treatment, secondaryOutcomes measure: Nivolumab treatment initiation date, secondaryOutcomes measure: Nivolumab dosage modification, secondaryOutcomes measure: Participant treatment duration, secondaryOutcomes measure: Reason for participant discharge, secondaryOutcomes measure: Participant adverse events (AEs), secondaryOutcomes measure: Management of participant adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Bayshore Specialty Rx Ltd., city: Mississauga, state: Ontario, zip: L5K 2L3, country: Canada, geoPoint lat: 43.5789, lon: -79.6583, hasResults: False